Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

3

Indication details

Control Arm
Single arm (Phase II)
FDA Therapeutic Indication
Patients with locally advanced or metastatic UC who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥5%
Tumour Type
Genitourinary Cancers
Tumour Sub-type
Urothelial Carcinoma
Tumour Stage
Locally advanced or metastatic
Tumour Sub-Group
PD-L1 expression ≥5%
Trial Name
IMvigor210 – Cohort 1
NCT Number
NCT02951767
Trial Phase
Phase II

Approval details

FDA Approval
FDA approval May 2016
EMA Approval
EMA (CHMP) June 2018 EC decision August 2018

Primary Outcome(s)

Primary Outcome(s)
ORR
Evaluated Outcome
ORR
Form(s)
Form 3

Outcome Data

PFS Control
4.1 months
ORR
28%
DoR
NR (11.1 months NE)

Adjustments

QoL Comment
QoL was not a prespecified endpoint

Score (after adjustments)

Preliminary non-curative score

3

Non-curative score

3

Comment
EMA (CHMP) June 2018 EC decision August 2018
FDA approval May 2016

Scorecard details

ESMO-MCBS version
ESMO-MCBS v1.1
Scorecard ID
355
Scorecard version
1
Issue date
11.11.2022
Last update
21.12.2023
Atezolizumab IMvigor210 – Cohort 1

PRELIMINARY SCORE

ORR

ADJUSTMENTS

Atezolizumab IMvigor210 – Cohort 1

SCORE

Overall Survival / Disease-Free Survival / Pathological Complete Response
Overall Survival
Progression-Free Survival
Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate
3
Overall Response Rate / Duration of Response
Genitourinary Cancers
Patients with locally advanced or metastatic UC who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥5%
Atezolizumab
Single arm (Phase II)

My watchlist

    pdf
    pptx

    Legend

    Information about symbols, abbrevations and color codes

    Red = negative
    Green = positive
    Grey = neutral
    ? Grey + ? = neutral with pending data
    DFS
    Disease-Free Survival
    DoR
    Duration of Response
    EFS
    Event-Free Survival
    HR
    Hazard Ratio
    NEB
    No evaluable benefit
    NI
    Non-inferiority Study
    ORR
    Overall Response Rate
    OS
    Overall Surival
    pCR
    Pathological Complete Response/Remission
    PFS
    Progression-Free Survival
    QoL
    Quality of Life
    RFS
    Relapse-Free Survival
    RR
    Response Rate

    QoL adjustments

    Other adjustments*

    Serious and disabling adverse effects

    Red = negative / deterioration

    Green = positive / improvement

    QoL adjustments

    Red = negative / deterioration

    Green = positive / improvement

    Other adjustments*

    Red = negative / deterioration

    Green = positive / improvement

    Serious and disabling adverse effects

    Red = negative / deterioration

    Green = positive / improvement

    * Other adjustments include:

    - Long-term plateau in the survival curve
    - Long-term plateau in the PFS curve
    - Early stopping or crossover
    - Only improved PFS mature data shows no OS advantage and no improved Qol.

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings
    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.